🚀 VC round data is live in beta, check it out!
Zhejiang Huahai Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zhejiang Huahai and similar public comparables like Edgewise Therapeutics, Voronoi, Zealand Pharma, Ajanta Pharma and more.
Zhejiang Huahai Overview
About Zhejiang Huahai
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company’s products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
Founded
2001
HQ
Employees
9.1K
Website
Sectors
Financials (LTM)
EV
$5B
Zhejiang Huahai Financials
Zhejiang Huahai reported last 12-month revenue of $1B and EBITDA of $259M.
In the same LTM period, Zhejiang Huahai generated $259M in EBITDA and $68M in net income.
Revenue (LTM)
Zhejiang Huahai P&L
In the most recent fiscal year, Zhejiang Huahai reported revenue of $1B and EBITDA of $381M.
Zhejiang Huahai expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $867M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $259M | XXX | $381M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $68M | XXX | $164M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $728M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zhejiang Huahai Stock Performance
Zhejiang Huahai has current market cap of $4B, and enterprise value of $5B.
Market Cap Evolution
Zhejiang Huahai's stock price is $2.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $4B | 3.6% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhejiang Huahai Valuation Multiples
Zhejiang Huahai trades at 3.7x EV/Revenue multiple, and 17.8x EV/EBITDA.
EV / Revenue (LTM)
Zhejiang Huahai Financial Valuation Multiples
As of April 18, 2026, Zhejiang Huahai has market cap of $4B and EV of $5B.
Equity research analysts estimate Zhejiang Huahai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang Huahai has a P/E ratio of 54.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.8x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 44.5x | XXX | 17.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.3x | XXX | XXX | XXX |
| P/E | 54.5x | XXX | 22.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 98.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhejiang Huahai Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zhejiang Huahai Margins & Growth Rates
Zhejiang Huahai's revenue in the last 12 month grew by 8%.
Zhejiang Huahai's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Zhejiang Huahai's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhejiang Huahai's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zhejiang Huahai Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | (39%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zhejiang Huahai Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhejiang Huahai | XXX | XXX | XXX | XXX | XXX | XXX |
| Edgewise Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Voronoi | XXX | XXX | XXX | XXX | XXX | XXX |
| Zealand Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ajanta Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Huahai M&A Activity
Zhejiang Huahai acquired XXX companies to date.
Last acquisition by Zhejiang Huahai was on XXXXXXXX, XXXXX. Zhejiang Huahai acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zhejiang Huahai
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZhejiang Huahai Investment Activity
Zhejiang Huahai invested in XXX companies to date.
Zhejiang Huahai made its latest investment on XXXXXXXX, XXXXX. Zhejiang Huahai invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zhejiang Huahai
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhejiang Huahai
| When was Zhejiang Huahai founded? | Zhejiang Huahai was founded in 2001. |
| Where is Zhejiang Huahai headquartered? | Zhejiang Huahai is headquartered in China. |
| How many employees does Zhejiang Huahai have? | As of today, Zhejiang Huahai has over 9K employees. |
| Is Zhejiang Huahai publicly listed? | Yes, Zhejiang Huahai is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Zhejiang Huahai? | Zhejiang Huahai trades under 600521 ticker. |
| When did Zhejiang Huahai go public? | Zhejiang Huahai went public in 2003. |
| Who are competitors of Zhejiang Huahai? | Zhejiang Huahai main competitors are Edgewise Therapeutics, Voronoi, Zealand Pharma, Ajanta Pharma. |
| What is the current market cap of Zhejiang Huahai? | Zhejiang Huahai's current market cap is $4B. |
| What is the current revenue of Zhejiang Huahai? | Zhejiang Huahai's last 12 months revenue is $1B. |
| What is the current revenue growth of Zhejiang Huahai? | Zhejiang Huahai revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Zhejiang Huahai? | Current revenue multiple of Zhejiang Huahai is 3.7x. |
| Is Zhejiang Huahai profitable? | Yes, Zhejiang Huahai is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zhejiang Huahai? | Zhejiang Huahai's last 12 months EBITDA is $259M. |
| What is Zhejiang Huahai's EBITDA margin? | Zhejiang Huahai's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Zhejiang Huahai? | Current EBITDA multiple of Zhejiang Huahai is 17.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.